AJNA BioSciences is a company focused on developing a new class of drugs derived from botanicals, aiming to address the increasing consumer demand for natural health solutions. They are currently developing two drug candidates, CBD for Autism Spectrum Disorder and Psilocybin for Generalized Anxiety Disorder, with a commitment to ethical and sustainable research practices. AJNA’s approach leverages the growing acceptance of psychedelic-assisted therapy and the FDA’s evolving regulations for botanical drugs, potentially paving the way for a new era of natural medicine.